Delveinsight

Fibromyalgia Market Insights, Epidemiology and Market Forecast-2028

DelveInsight Business Research LLP

 

Albany, NY -- (SBWIRE) -- 08/21/2019 -- Fibromyalgia Market Insights, Epidemiology and Market Forecast-2028

1. Fibromyalgia prevalence in the general population was from 0.5% to 5%.
2. Fibromyalgia global mean prevalence was 2.7 % and the mean rate was 3.1 % in America, 2.5 % in Europe while for Asia it was reported 1.7%.
3. Fibromyalgia means prevalence was 4.2 % in women and in men 1.4 %, with a female-to-male ratio of 3:1.

(Albany, US) DelveInsight launched a new report on Fibromyalgia Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Fibromyalgia market report covers a descriptive overview and comprehensive insight of the Fibromyalgia epidemiology and Fibromyalgia market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Fibromyalgia market report provides insights on the current and emerging therapies.
3. Fibromyalgia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Fibromyalgia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fibromyalgia market.

Request for sample pages

"A peak prevalence in men in middle age, whereas in women the prevalence steadily increased with age."

Fibromyalgia therapeutic market is segmented into antidepressants (Cymbalta, Savella, etc.), anticonvulsants (Lyrica and others), muscle relaxants, and analgesics. FDA approved drugs such as Lyrica, Cymbalta, Savella, and others are used widely for Fibromyalgia treatment, although, Savella is not approved for use in pediatric patients. Among these drugs, Cymbalta and Savella change serotonin and norepinephrine to help control pain levels. Lyrica plays an important role in Fibromyalgia treatment, with its precursor gabapentin, which has analgesic, anxiolytic, and antiepileptic effects. Other antidepressant drugs such as Elavil and cyclobenzaprine Flexeril can also be used to treat Fibromyalgia. It is strongly recommended to avoid opioid narcotic medications for treating Fibromyalgia as these drugs are not helpful to most people and can cause greater pain sensitivity or make pain persist. Sometimes Tramadol may be used to treat Fibromyalgia pain if short-term use of an opioid narcotic is needed.
While drug treatments are available for Fibromyalgia symptoms, yet their efficacy varies from patient to patient, and significant side effects can limit benefits or preclude the use of these medications. Thus, there is a continued need for additional effective and tolerable Fibromyalgia treatment options for patients to improve their daily functioning. Also, Fibromyalgia is hard to diagnose as most of the symptoms are associated with other diseases. This, in turn, lowers the diagnosis rate of patients having Fibromyalgia, hampering the growth of Fibromyalgia market treatment.
However, the increase in Fibromyalgia prevalence and awareness across the globe is boosting the Fibromyalgia market treatment. The launch of innovative and better drugs for Fibromyalgia treatment is expected to propel the Fibromyalgia treatment market in the upcoming years.
To summarize, Fibromyalgia market will be improved with drugs receiving special designations by regulatory bodies, resulting in the shorter developmental timeline. All these factors shall lead to a significant increase in Fibromyalgia market size during the forecast period (2018–2028).

The launch of emerging therapies is expected to significantly impact the Fibromyalgia treatment scenario in the upcoming years:-

Drugs covered
1. IMC-1
2. NYX-2925
3. ASP0819
And many others

The key players in Fibromyalgia market are:
1. Innovativemed concepts
2. Astellas Pharma
3. Aptinyx
And many others

Table of contents

1. Report Introduction
2. Fibromyalgia Market Overview at a Glance
3. Fibromyalgia Disease Background and Overview
4. Fibromyalgia Epidemiology and Patient Population
5. Fibromyalgia Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.Spain
5.2.5.United Kingdom
5.3. Japan
6. Fibromyalgia Treatment & Medical Practices
6.1. Fibromyalgia Treatment Algorithm
7. Fibromyalgia Marketed Therapies
7.1. Savella: Forest Pharmaceuticals
7.2. LYRICA: Pfizer Pharmaceuticals
8. Fibromyalgia Key Emerging Therapies
8.1. Key Cross Competition
8.2. IMC-1 : Innovativemed concepts
8.3. NYX-2925 : Aptinyx
8.4. ASP0819 : Astellas Pharma
9. Fibromyalgia Market Size
10. 7MM Fibromyalgia Country-Wise Market Analysis
10.1. United States
10.2. Germany
10.4. United Kingdom
10.5. Spain
10.6. Italy
10.7. Japan
11. Market Drivers
12. Market Barriers
13. Appendix
14. Fibromyalgia Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight